APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psoriatic Arthritis Therapeutics Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Psoriatic Arthritis Therapeutics Drug Market Outlook and Growth Opportunities 2026

30 December 2025190 pages

Choose your research edition.

Industry ResearchPsoriatic Arthritis Therapeutics Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Psoriatic Arthritis Therapeutics Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Psoriatic Arthritis Therapeutics Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psoriatic Arthritis Therapeutics Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Psoriatic Arthritis Therapeutics Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Psoriatic Arthritis Therapeutics Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Psoriatic Arthritis Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psoriatic Arthritis Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psoriatic Arthritis Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Psoriatic Arthritis Therapeutics Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Psoriatic Arthritis Therapeutics Drug market include Novartis, Eli Lilly, Pfizer, Amgen, AbbVie, UCB, Janssen Biotech, CELGENE CORPORATION and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Psoriatic Arthritis Therapeutics Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psoriatic Arthritis Therapeutics Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psoriatic Arthritis Therapeutics Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Psoriatic Arthritis Therapeutics Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Psoriatic Arthritis Therapeutics Drug Segment by Company

Novartis

Eli Lilly

Pfizer

Amgen

AbbVie

UCB

Janssen Biotech

CELGENE CORPORATION

Bristol-Myers Squibb

Biogen

Psoriatic Arthritis Therapeutics Drug Segment by Type

Interleukin Inhibitors

NF Inhibitors

PDE4 Inhibitors

Others

Psoriatic Arthritis Therapeutics Drug Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Psoriatic Arthritis Therapeutics Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Psoriatic Arthritis Therapeutics Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Psoriatic Arthritis Therapeutics Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Psoriatic Arthritis Therapeutics Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Psoriatic Arthritis Therapeutics Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriatic Arthritis Therapeutics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psoriatic Arthritis Therapeutics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriatic Arthritis Therapeutics Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Psoriatic Arthritis Therapeutics Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psoriatic Arthritis Therapeutics Drug industry.

Chapter 3: Detailed analysis of Psoriatic Arthritis Therapeutics Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Psoriatic Arthritis Therapeutics Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Psoriatic Arthritis Therapeutics Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Psoriatic Arthritis Therapeutics Drug Industry Trends Table 2. Psoriatic Arthritis Therapeutics Drug Industry Drivers Table 3. Psoriatic Arthritis Therapeutics Drug Industry Opportunities and Challenges Table 4. Psoriatic Arthritis Therapeutics Drug Industry Restraints Table 5. Global Psoriatic Arthritis Therapeutics Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Psoriatic Arthritis Therapeutics Drug Revenue Share by Company (2021-2026) Table 7. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Company (2021-2026) Table 9. Global Psoriatic Arthritis Therapeutics Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Psoriatic Arthritis Therapeutics Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Psoriatic Arthritis Therapeutics Drug Key Company Manufacturing Base & Headquarters Table 12. Global Psoriatic Arthritis Therapeutics Drug Company, Product Type & Application Table 13. Global Psoriatic Arthritis Therapeutics Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Psoriatic Arthritis Therapeutics Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Interleukin Inhibitors Table 18. Significant Companies of NF Inhibitors Table 19. Significant Companies of PDE4 Inhibitors Table 20. Significant Companies of Others Table 21. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Type (2021-2026) Table 25. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Type (2027-2032) Table 26. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type (2021-2026) Table 30. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Retail Pharmacies Table 32. Significant Companies of Online Pharmacies Table 33. Significant Companies of Hospital Pharmacies Table 34. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Application (2021-2026) Table 38. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Application (2027-2032) Table 39. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application (2021-2026) Table 43. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application (2027-2032) Table 44. Global Psoriatic Arthritis Therapeutics Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Psoriatic Arthritis Therapeutics Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Psoriatic Arthritis Therapeutics Drug Sales Market Share by Region (2021-2026) Table 47. Global Psoriatic Arthritis Therapeutics Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Psoriatic Arthritis Therapeutics Drug Sales Market Share by Region (2027-2032) Table 49. Global Psoriatic Arthritis Therapeutics Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Region (2021-2026) Table 52. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Region (2027-2032) Table 54. Global Psoriatic Arthritis Therapeutics Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Psoriatic Arthritis Therapeutics Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Psoriatic Arthritis Therapeutics Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Psoriatic Arthritis Therapeutics Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Psoriatic Arthritis Therapeutics Drug Sales Market Share by Country (2021-2026) Table 60. Global Psoriatic Arthritis Therapeutics Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Psoriatic Arthritis Therapeutics Drug Sales Market Share by Country (2027-2032) Table 62. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Psoriatic Arthritis Therapeutics Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Psoriatic Arthritis Therapeutics Drug Sales Value Market Share by Country (2027-2032) Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Novartis Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 70. Novartis Recent Development Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Eli Lilly Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 75. Eli Lilly Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Pfizer Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 80. Pfizer Recent Development Table 81. Amgen Company Information Table 82. Amgen Business Overview Table 83. Amgen Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Amgen Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 85. Amgen Recent Development Table 86. AbbVie Company Information Table 87. AbbVie Business Overview Table 88. AbbVie Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. AbbVie Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 90. AbbVie Recent Development Table 91. UCB Company Information Table 92. UCB Business Overview Table 93. UCB Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. UCB Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 95. UCB Recent Development Table 96. Janssen Biotech Company Information Table 97. Janssen Biotech Business Overview Table 98. Janssen Biotech Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Janssen Biotech Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 100. Janssen Biotech Recent Development Table 101. CELGENE CORPORATION Company Information Table 102. CELGENE CORPORATION Business Overview Table 103. CELGENE CORPORATION Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. CELGENE CORPORATION Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 105. CELGENE CORPORATION Recent Development Table 106. Bristol-Myers Squibb Company Information Table 107. Bristol-Myers Squibb Business Overview Table 108. Bristol-Myers Squibb Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bristol-Myers Squibb Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 110. Bristol-Myers Squibb Recent Development Table 111. Biogen Company Information Table 112. Biogen Business Overview Table 113. Biogen Psoriatic Arthritis Therapeutics Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Biogen Psoriatic Arthritis Therapeutics Drug Product Portfolio Table 115. Biogen Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Psoriatic Arthritis Therapeutics Drug Distributors List Table 119. Psoriatic Arthritis Therapeutics Drug Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Psoriatic Arthritis Therapeutics Drug Product Image Figure 2. Global Psoriatic Arthritis Therapeutics Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Psoriatic Arthritis Therapeutics Drug Sales (2021-2032) & (W Units) Figure 5. Global Psoriatic Arthritis Therapeutics Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Psoriatic Arthritis Therapeutics Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Interleukin Inhibitors Image Figure 10. NF Inhibitors Image Figure 11. PDE4 Inhibitors Image Figure 12. Others Image Figure 13. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type (2021-2032) Figure 19. Retail Pharmacies Image Figure 20. Online Pharmacies Image Figure 21. Hospital Pharmacies Image Figure 22. Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application (2021-2032) Figure 28. Global Psoriatic Arthritis Therapeutics Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Psoriatic Arthritis Therapeutics Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Psoriatic Arthritis Therapeutics Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Psoriatic Arthritis Therapeutics Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Psoriatic Arthritis Therapeutics Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Interleukin Inhibitors
  • NF Inhibitors
  • PDE4 Inhibitors
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Novartis
  • Eli Lilly
  • Pfizer
  • Amgen
  • AbbVie
  • UCB
  • Janssen Biotech
  • CELGENE CORPORATION
  • Bristol-Myers Squibb
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032)
  4. 1.2.2 Global Psoriatic Arthritis Therapeutics Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Psoriatic Arthritis Therapeutics Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Psoriatic Arthritis Therapeutics Drug Market Dynamics
  1. 2.1 Psoriatic Arthritis Therapeutics Drug Industry Trends
  2. 2.2 Psoriatic Arthritis Therapeutics Drug Industry Drivers
  3. 2.3 Psoriatic Arthritis Therapeutics Drug Industry Opportunities and Challenges
  4. 2.4 Psoriatic Arthritis Therapeutics Drug Industry Restraints
3 Psoriatic Arthritis Therapeutics Drug Market by Company
  1. 3.1 Global Psoriatic Arthritis Therapeutics Drug Company Revenue Ranking in 2025
  2. 3.2 Global Psoriatic Arthritis Therapeutics Drug Revenue by Company (2021-2026)
  3. 3.3 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Psoriatic Arthritis Therapeutics Drug Average Price by Company (2021-2026)
  5. 3.5 Global Psoriatic Arthritis Therapeutics Drug Company Ranking (2024-2026)
  6. 3.6 Global Psoriatic Arthritis Therapeutics Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Psoriatic Arthritis Therapeutics Drug Company Product Type and Application
  8. 3.8 Global Psoriatic Arthritis Therapeutics Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Psoriatic Arthritis Therapeutics Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Psoriatic Arthritis Therapeutics Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Psoriatic Arthritis Therapeutics Drug Market by Type
  1. 4.1 Psoriatic Arthritis Therapeutics Drug Type Introduction
  2. 4.1.1 Interleukin Inhibitors
  3. 4.1.2 NF Inhibitors
  4. 4.1.3 PDE4 Inhibitors
  5. 4.1.4 Others
  6. 4.2 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type
  7. 4.2.1 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type
  11. 4.3.1 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type (2021-2032)
5 Psoriatic Arthritis Therapeutics Drug Market by Application
  1. 5.1 Psoriatic Arthritis Therapeutics Drug Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application
  6. 5.2.1 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Psoriatic Arthritis Therapeutics Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Psoriatic Arthritis Therapeutics Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application
  10. 5.3.1 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application (2021-2032)
6 Psoriatic Arthritis Therapeutics Drug Regional Sales and Value Analysis
  1. 6.1 Global Psoriatic Arthritis Therapeutics Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psoriatic Arthritis Therapeutics Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Psoriatic Arthritis Therapeutics Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Psoriatic Arthritis Therapeutics Drug Sales by Region (2027-2032)
  5. 6.3 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Psoriatic Arthritis Therapeutics Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032)
  12. 6.6.2 North America Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032)
  21. 6.9.2 South America Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Psoriatic Arthritis Therapeutics Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Psoriatic Arthritis Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
7 Psoriatic Arthritis Therapeutics Drug Country-level Sales and Value Analysis
  1. 7.1 Global Psoriatic Arthritis Therapeutics Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Psoriatic Arthritis Therapeutics Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Psoriatic Arthritis Therapeutics Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Psoriatic Arthritis Therapeutics Drug Sales by Country (2027-2032)
  6. 7.4 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Psoriatic Arthritis Therapeutics Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Psoriatic Arthritis Therapeutics Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Psoriatic Arthritis Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Psoriatic Arthritis Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Psoriatic Arthritis Therapeutics Drug Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Psoriatic Arthritis Therapeutics Drug Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Psoriatic Arthritis Therapeutics Drug Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Psoriatic Arthritis Therapeutics Drug Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Psoriatic Arthritis Therapeutics Drug Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 UCB
  32. 8.6.1 UCB Company Information
  33. 8.6.2 UCB Business Overview
  34. 8.6.3 UCB Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 UCB Psoriatic Arthritis Therapeutics Drug Product Portfolio
  36. 8.6.5 UCB Recent Developments
  37. 8.7 Janssen Biotech
  38. 8.7.1 Janssen Biotech Company Information
  39. 8.7.2 Janssen Biotech Business Overview
  40. 8.7.3 Janssen Biotech Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Biotech Psoriatic Arthritis Therapeutics Drug Product Portfolio
  42. 8.7.5 Janssen Biotech Recent Developments
  43. 8.8 CELGENE CORPORATION
  44. 8.8.1 CELGENE CORPORATION Company Information
  45. 8.8.2 CELGENE CORPORATION Business Overview
  46. 8.8.3 CELGENE CORPORATION Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CELGENE CORPORATION Psoriatic Arthritis Therapeutics Drug Product Portfolio
  48. 8.8.5 CELGENE CORPORATION Recent Developments
  49. 8.9 Bristol-Myers Squibb
  50. 8.9.1 Bristol-Myers Squibb Company Information
  51. 8.9.2 Bristol-Myers Squibb Business Overview
  52. 8.9.3 Bristol-Myers Squibb Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Psoriatic Arthritis Therapeutics Drug Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Psoriatic Arthritis Therapeutics Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Psoriatic Arthritis Therapeutics Drug Product Portfolio
  60. 8.10.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Psoriatic Arthritis Therapeutics Drug Value Chain Analysis
  2. 9.1.1 Psoriatic Arthritis Therapeutics Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Psoriatic Arthritis Therapeutics Drug Sales Mode & Process
  6. 9.2 Psoriatic Arthritis Therapeutics Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Psoriatic Arthritis Therapeutics Drug Distributors
  9. 9.2.3 Psoriatic Arthritis Therapeutics Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst